Cortactin is a ubiquitously expressed protein involved in cortical-actin assembly/nucleation and dynamic rearrangement of actin. 7-9 As a scaffold protein, the N-terminal acidic domain of cortactin binds to the actin-related protein 2/3 complex. The repeat region binds to F-actin. The proline-rich domain is phosphorylated by various kinases, and the C-terminal Src homology 3 domain interacts with neuronal Wiskott-Aldrich syndrome Objective-Cortactin translocates to the cell periphery in vascular endothelial cells (ECs) on cortical-actin assembly in response to pulsatile shear stress. Because cortactin has putative sites for AMP-activated protein kinase (AMPK) phosphorylation and sirtuin 1 (SIRT1) deacetylation, we examined the hypothesis that AMPK and SIRT1 coregulate cortactin dynamics in response to shear stress. Approach and Results-Analysis of the ability of AMPK to phosphorylate recombinant cortactin and oligopeptides whose sequences matched AMPK consensus sequences in cortactin pointed to Thr-401 as the site of AMPK phosphorylation. Mass spectrometry confirmed Thr-401 as the site of AMPK phosphorylation. Immunoblot analysis with AMPK siRNA and SIRT1 siRNA in human umbilical vein ECs and EC-specific AMPKα2 knockout mice showed that AMPK phosphorylation of cortactin primes SIRT1 deacetylation in response to shear stress. Immunoblot analyses with cortactin siRNA in human umbilical vein ECs, phospho-deficient T401A and phospho-mimetic T401D mutant, or aceto-deficient (9K/R) and aceto-mimetic (9K/Q) showed that cortactin regulates endothelial nitric oxide synthase activity. Confocal imaging and sucrose-density gradient analyses revealed that the phosphorylated/deacetylated cortactin translocates to the EC periphery facilitating endothelial nitric oxide synthase translocation from lipid to nonlipid raft domains. Knockdown of cortactin in vitro or genetic reduction of cortactin expression in vivo in mice substantially decreased the endothelial nitric oxide synthase-derived NO bioavailability. In vivo, atherosclerotic lesions increase in ApoE -/-/cortactin +/mice, when compared with ApoE -/-/cortactin +/+ littermates. Conclusions-AMPK phosphorylation of cortactin followed by SIRT1 deacetylation modulates the interaction of cortactin and cortical-actin in response to shear stress. Functionally, this AMPK/SIRT1 coregulated cortactin-F-actin dynamics is required for endothelial nitric oxide synthase subcellular translocation/activation and is atheroprotective. (D.A.J.) . The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
T he pattern of local blood flow in the arterial tree affects the endothelial phenotype. Blood flow in the straight section of the arterial tree is atheroprotective, which exerts anti-inflammatory, antioxidative, and antiproliferative effects on vascular endothelial cells (ECs). 1-3 AMP-activated protein kinase (AMPK) and sirtuin 1 (SIRT1), activated by various metabolic and environmental stresses, are 2 key molecules in ECs regulated by atheroprotective flow. In vitro, pulsatile shear stress (PS), mimicking atheroprotective flow, activates endothelial nitric oxide synthase (eNOS) through AMPK and SIRT1. 4 Flow regulation of AMPK and SIRT1 in relation to the atheroprotective phenotype is evidenced in mice with ablated AMPKα2 or SIRT1. These mice, when crossed with ApoE -/-, have enhanced atherosclerosis both in atheroprone and atheroprotective regions of the aorta. 5 AMPK and SIRT1 synergistically regulate common downstream targets, as exemplified by the coregulation of eNOS in ECs and peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α) in myocytes. 4, 6 Here, AMPK phosphorylation of eNOS and PGC1α primes their deacetylation by SIRT1. protein (WASP) and WASP-interacting protein. In ECs, cortactin is functionally linked to cytoskeletal remodeling, angiogenesis, leukocyte transmigration, and vascular permeability. [10] [11] [12] [13] In terms of post-translational modifications of cortactin, the Src family kinases FER and Syk phosphorylate cortactin at Tyr-421, Tyr-466, and Tyr-482. [14] [15] [16] [17] PAK3 (p21-activated kinase 3) phosphorylates Ser-113, and ERK (extracellular signal-regulated kinases) phosphorylates Ser-405 and Ser-418. [18] [19] [20] Phosphorylation of these sites by either Tyr or Ser/Thr kinase is functionally linked to actin dynamics and assembly. Moreover, SIRT1/2 can interact with and deacetylate cortactin to affect its binding to F-actin. 21 Initial localization of eNOS in the lipid rafts of the EC membrane is essential for eNOS activation. On exposure to shear stress, eNOS translocates from caveolae to the cytoplasm, where eNOS is phosphorylated by Akt. [22] [23] [24] Reduction of eNOS in caveolae by cholesterol depletion or inhibition of eNOS myristoylation decreases stimulus-induced eNOS activation. [25] [26] [27] Much evidence indicates that the interaction of caveolae with actin-based cytoskeleton and the dynamic remodeling of F-actin affect eNOS activity. 28, 29 Indeed, both cytochalasin B disruption and phalloidin stabilization of F-actin diminish the flow-induced NO release in the rabbit abdominal aorta. 30 In addition, several actin-binding proteins, including dynamin-2, NOSIP (nitric oxide synthase interacting protein), and NOSTRIN (nitric oxide synthase traffic inducer) are involved in eNOS trafficking and activity. [31] [32] [33] Although cortactin has been reported to translocate to the cell periphery on cortical-actin assembly in response to shear stress, 10 the involvement of cortactin in shear-stress-modulated eNOS and EC function is unknown.
Cortactin has both AMPK phosphorylation and SIRT1 deacetylation consensus sequences. 21, 34, 35 This report examines the hypothesis that cortactin is coregulated by AMPK and SIRT1 similar to their regulation of eNOS and PGC1α. We found that AMPK and SIRT1 not only coregulate cortactin but also play a key role in the structural and functional integrity of caveolae and are essential for shear-stress activation of eNOS. Hence, decreased expression of cortactin in the vascular wall hampers eNOS-derived NO bioavailability and increases atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

AMPK Phosphorylates Cortactin Thr-401
A genome-wide bioinformatics analysis for the consensus sequence of AMPK revealed that cortactin Ser-348 and Thr-401 located in the helix and proline-rich domains, respectively, could be AMPK phosphorylation sites ( Figure 1A ). 36 Interestingly, these 2 sites are conserved among various mammalian species (Figure I in the online-only Data Supplement). Incubation of [γ-32 P]ATP with recombinant cortactin and AMPK increased the level of 32 P-labeled cortactin ( Figure  1B ), which suggested that AMPK can phosphorylate cortactin in vitro. To validate, AMPK can phosphorylate cortactin Ser-348 and Thr-401, the degree of AMPK phosphorylation of 2 oligopeptides composed of the amino acids flanking Ser-348 and Thr-401 was compared with the SAMS (substrate for AMP-activated protein kinase) peptide, the canonical AMPK substrate, and peptides with Ala substituted at the putative sites of phosphorylation (ie, S348A and T401A). We found that AMPK phosphorylated the 2 wild-type cortactin peptides to the same extent as the positive-control SAMS peptide. The Ala substitution of Thr-401, but not Ser-348, decreased 32 P incorporation to the level observed for samples without AMPK ( Figure 1C ), which suggests that Thr-401 could be an AMPK phosphorylation site. To determine further the site of AMPK phosphorylation of cortactin, we treated human umbilical vein ECs (HUVECs) with resveratrol, a polyphenol activating/inducing AMPK and SIRT1, or 5-aminoimidazole-4-carboxamide ribonucleotide, an AMPK activator. Cortactin was immunoprecipitated from the protein extracts and subjected to tandem mass spectrometry analysis. By comparing the m/z values for the observed fragment ions with those calculated for the phosphorylated Thr-401-bearing tryptic peptide ( Table  I in 
AMPK/SIRT1 Coregulates Cortactin
Given that PS activates both AMPK and SIRT1 in ECs and SIRT1 deacetylates cortactin, 4, 21 we examined whether cortactin can be coregulated by AMPK and SIRT1 in ECs responding to PS. HUVECs were subjected to PS for various times followed by immunoprecipitation of cortactin and immunoblotting for acetylated cortactin. Deacetylation of cortactin was evident as early as 4 hours, and the PS-reduced cortactin acetylation persisted for at least 16 hours ( Figure 2A ). Knockdown of either AMPK or SIRT1 by siRNA blocked PS-reduced cortactin acetylation ( Figure 2B ). Similar to PS, resveratrol treatment decreased cortactin acetylation in HUVECs ( Figure 2C ). Knockdown of AMPK or SIRT1 also blocked the resveratrolreduced cortactin acetylation ( Figure 2C ). To further investigate the AMPK/SIRT1 coregulation of cortactin, HUVECs were treated with nicotinamide, an SIRT1-specific inhibitor before PS stimulation. Deacetylation of cortactin occurred at 4 hours under PS. However, cortactin remained acetylated if HUVECs were pretreated with nicotinamide ( Figure 2D ). Moreover, the PS-reduced cortactin acetylation was not observed in lung ECs isolated from EC-specific AMPKα2 -/mice ( Figure 2E ). Next, we mutated cortactin Thr-401 to Ala (T401A) or Asp (T401D), the respective phospho-deficient and phospho-mimetic mutants. When expressed in cortactin heterozygous (cortactin +/-) murine embryonic fibroblasts, 
Cortactin Regulates eNOS Activity
Because AMPK and SIRT1 coregulate cortactin at the posttranslational level and because shear stress is a physiological stimulation regulating eNOS, we next investigated the involvement of cortactin in PS-activated eNOS. PS increased eNOS phosphorylation at Ser-633 and Ser-1177 ( Figure 3A) , which is indicative of increased eNOS activity. This increased phosphorylation was attenuated by cortactin knockdown, which suggests that PS induction of eNOS is cortactin dependent. Next, we examined whether cortactin-dependent eNOS activation is regulated through AMPK and SIRT1. HUVECs were transfected with cortactin phospho-deficient T401A or phospho-mimic T401D mutants and then infected with adenovirus overexpressing SIRT1 (Ad-SIRT1) to mimic PS induction of SIRT1. Overexpression of SIRT1 increased NO production in cells expressing cortactin T401D, but not in cells transfected with cortactin T401A ( Figure 3B ). To further demonstrate that eNOS activity was modulated by cortactin in an AMPK/SIRT1-dependent manner, we overexpressed eNOS with the cortactin T401A or T401D mutant in cortactin +/murine embryonic fibroblasts and infected adenovirus overexpressing SIRT1 to simulate PS activation of AMPK/ SIRT1. Cells transfected with cortactin T401D and infected with Ad-SIRT1 showed higher eNOS activity, as indicated by an increase of phosphorylation at eNOS Ser-633 ( Figure 3C ). Likewise, overexpression of constitutively active AMPK (Ad-AMPK-CA) increased NO production in HUVECs transfected with aceto-deficient mutants (cortactin 9K/R), but not with aceto-mimetic mutants (cortactin 9K/Q; Figure 3D ). Furthermore, cortactin +/murine embryonic fibroblasts overexpressing cortactin 9K/R infected with Ad-AMPK-CA showed increased eNOS phosphorylation. In contrast, murine embryonic fibroblasts overexpressing cortactin 9K/Q mutants did not respond to Ad-AMPK-CA transfection ( Figure 3E ). To further delineate the role of AMPK/SIRT1 in activating eNOS via cortactin, we cotransfected cortactin T401D/9K/R (phospho-mimetic/aceto-deficient mutant) or cortactin T401A/9K/Q (phospho-deficient/aceto-mimetic mutant) with a plasmid encoding eNOS in human embryonic kidney 293 cells to detect NO production. Cells overexpressing cortactin T401D/9K/R showed increased eNOS phosphorylation and NO production ( Figure 3F and 3G), which further confirms that phosphorylated/deacetylated cortactin modulates eNOS activity.
AMPK/SIRT1-Cortactin Regulation of eNOS Trafficking
Because the integrity of actin cytoskeletal is required for shear stress-activated eNOS and deacetylated cortactin increases its interaction with F-actin, 34 we next examined the impact of AMPK/SIRT1 on the cortactin-actin association in relation to eNOS translocation and activity. We first knocked down AMPK or SIRT1 with siRNA and then examined the corticalactin association under PS. The association of cortactin and F-actin was indicated by the degree of colocalization observed by using double immunofluorescent staining. Confocal microscopy showed that PS enhanced the cortactin interaction with cortical-actin, and siRNA knockdown of AMPK or SIRT1 inhibited this interaction ( Figure 4A ). Cortical-actin is important for the formation and function of caveolae. 37, 38 eNOS activation by shear stress requires eNOS translocation from caveolae to the cytoplasm, and disruption of F-actin or lipid rafts blunts shear stress activation of eNOS. 27, 39 Because AMPK/SIRT1 coregulated cortactin is functionally related to eNOS activity (demonstrated in Figure 3 ), we next investigated the role of cortactin-actin assembly in eNOS trafficking in response to PS. Sucrosedensity gradient analysis showed that under static conditions, eNOS, cortactin, actin, and caveolin-1 (a caveolae marker) are distributed in both lipid raft and nonlipid raft fractions ( Figure 4B ). PS shifted eNOS, cortactin, actin, and caveolin-1 from lipid raft to nonlipid raft fractions. Of note, cortactin siRNA knockdown stimulated eNOS, actin, and caveolin-1 to localize to the nonlipid raft fractions regardless of static or PS conditions ( Figure 4B and 4C). Translocation of eNOS, actin, and caveolin-1 out of the lipid rafts was also observed in ECs treated with cytochalasin D ( Figure III Figure 4E ). Importantly, cortactin knockdown abrogated eNOS translocation and activation in response to PS stimuli ( Figure 4E ).
Cortactin-Dependent eNOS Activation in the Vascular Wall
Because the systemic knockout of cortactin is embryonic lethal, 40 we used cortactin +/mice and their cortactin +/+ littermates to study the role of AMPK/SIRT1 coregulation of cortactin in the vascular wall. One possible mechanism for cortactin regulation of eNOS trafficking is that cortactin is required for caveolae formation. To test this hypothesis, we compared endothelial caveolae in cortactin +/+ with that in cortactin +/mice. Electron micrographs shown in Figure 5A reveal that endothelium from the wild-type animals had ≈2±0.2 per micrometer caveolae in both apical and basolateral membranes. However, the amount of caveolae was greatly reduced in the cortactin +/endothelium (1±0.1 per micrometer in apical and 1.5±0.1 per micrometer in basolateral membranes). Cortactin, F-actin, and eNOS subcellular location in the vascular wall were compared by en face staining of endothelium in aortas from cortactin +/+ and cortactin +/mice. Thoracic aorta of cortactin +/+ mice showed cortactin, F-actin, and eNOS colocalization at cell-cell junctions of endothelium but to a much lesser extent in corresponding regions of cortactin +/mice ( Figure 5B ). Immunoblotting with phospho-eNOS and cortactin antibodies showed decreased eNOS phosphorylation in cortactin +/aortas ( Figure 5C ). The decreased eNOS phosphorylation in cortactin +/mice was associated with both impaired NO production ( Figure 5D ) and flow-induced vessel dilation ( Figure 5E) . 
Cortactin Exerts an Atheroprotective Effect
To determine whether the lower level of NO in vessels of cortactin +/mice negatively affected endothelial function, we compared the expression of chemoattractant and adhesion molecules in the thoracic aortas of cortactin +/+ and cortactin +/mice. The mRNA levels of E-selectin, monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 were higher in cortactin +/than in cortactin +/+ mouse aortas ( Figure 6A ). This difference was mainly found in the intima (endothelium) but not in media and adventitia ( Figure 6B ). To determine whether the endothelial dysfunction in cortactin +/mice were atherogenic, we introduced an ApoE -/background into cortactin +/mice to generate ApoE -/-/cortactin +/mice and their ApoE -/-/cortactin +/+ littermates. The 2 groups were fed an atherogenic diet for 10 weeks, and atherosclerotic lesions in aortas were quantified and compared. The mean lesion area in thoracic aortas was ≈1.5-fold larger for ApoE -/-/cortactin +/than for ApoE -/-/cortactin +/+ mice (6.5±1.7% versus 3.0±0.4%; Figure 6C and 6D). In addition, the aortic arch lesion area and total lesion area (the sum of aortic arch, thoracic aorta, and abdominal aorta) were larger in the ApoE -/-/cortactin +/than in the ApoE -/-/cortactin +/+ mice (46.4±4.5% versus 24.4±3.2% and 13.6±5.3% versus 9.3±3.5%; Figure 6C , 6E, and 6F). Because the serum lipid profiles and M1 and M2 polarization in the isolated macrophages from the 2 groups of animals were comparable (Table II and 
Discussion
Atherosclerotic lesions develop preferentially at branches, bifurcations, and the aortic root where the endothelium is exposed to disturbed blood flow patterns. Straight segments of the arterial tree are largely athero-resistant, in part, via laminar flow-activated AMPK and SIRT1. 4, 5 We and others showed that AMPK and SIRT1 activate eNOS via posttranslational mechanisms in ECs in response to shear stress. Shear-stress activation of eNOS may rely on the integrity of actin-based cytoskeleton, 30, 41, 42 which suggests an F-actinrelated mechanism as a prerequisite for AMPK/SIRT1 phosphorylation/deacetylation of eNOS. In this report, we show that AMPK phosphorylation of cortactin followed by SIRT1 deacetylation modulates the interaction of cortactin and cortical-actin. In terms of function, this AMPK/SIRT1 coregulated cortactin-F-actin dynamics directs eNOS subcellular translocation and activation. The AMPK phosphorylation site Thr-401 is located in the proline-rich domain (residues 327-494) of cortactin and harbors several Tyr and Ser/Thr phosphorylation sites. The phosphorylation of Tyr-421, Tyr-466, and Tyr-482 by Src kinase regulates actin assembly by modulating cortactin binding to neuronal WASP, MLCK (myosin light-chain kinase), and dynamin-2. [43] [44] [45] ERK phosphorylation of Ser-405 and Ser-418 initiates actin-related protein 2/3-dependent actin nucleation via neuronal WASP. 20 In addition, recent phosphoproteomic analysis indicates that Akt phosphorylates Thr-401. 46 This phosphorylation event is involved in migration and invasion of the breast cancer cell line MCF-10A. Ser/Thr versus Tyr phosphorylation of cortactin may differentially affect actin assembly because Ser/Thr phosphorylation affects actin polymerization, whereas Tyr phosphorylation regulates focal adhesion turnover. 47 In addition, because Tyr phosphorylation alone is insufficient for subcellular translocation of cortactin responding to shear stress or a receptor agonist, 10,48 the interplay of AMPK/SIRT1 on cortactin-actin assembly would be functionally different from Src tyrosine regulation. Indeed, AMPK or SIRT1 knockdown has little effect on shear-stress-induced stress fiber formation and alignment ( Figure 4A ). This result further suggests that although AMPK/SIRT1 coregulation of cortactin-F-actin dynamics is required for eNOS activation, this mode of regulation is not involved in the actin cytoskeletal remodeling that would otherwise be regulated by ERK. 47 Here, 2 mechanisms are likely involved in AMPK/SIRT1-induced cortactin-actin assembly. First, AMPK phosphorylation of cortactin proline-rich domain induces a conformational change of F-actin-binding repeats and thus favoring SIRT1 deacetylation to promote cortical-actin remodeling. AMPK phosphorylation of cortactin may also liberate Src homology 3 domains from intramolecular binding to the proline-rich domain. Second, SIRT1 deacetylation enables cortactincortical-actin assembly through the positively charged Lys patch (Lys-87, Lys-124, Lys-161, Lys-189, Lys-198, Lys-235, Lys-272, Lys-309, and Lys-319). AMPK and SIRT1 also synergistically regulate eNOS and PGC1α similar to that of cortactin 4, 6 However, knockdown of cortactin had little effect on PGC1α expression in HUVECs ( Figure VI in the onlineonly Data Supplement), which suggests that cortactin is not an upstream regulator of PGC1α. Thus, AMPK may phosphorylate cortactin, eNOS, and PGC1α, which primes for the deacetylation of these 3 molecules independently. The assembly of cortical-actin is required for the organization and localization of caveolae near the plasma membrane. 49 Furthermore, F-actin association with membrane caveolae stabilizes caveolae structure and controls caveolae endocytosis. 29, [50] [51] [52] Here, our results suggest that caveolae formation requires cortactin because cortactin knockdown shifts caveolin-1 and actin to the nonlipid fractions ( Figure 4B ). In vivo, the reduced level of caveolae in the vascular wall of cortactin +/mice ( Figure 5A ) suggests that cortactin is an integral part of the F-actin apparatus required to maintain caveolae in the vasculature. Knockdown of AMPK or SIRT1 abolishes cortactin-F-actin interaction and also shifts caveolin-1 (a caveolae marker) to the nonlipid raft regions (Figure 4 ; Figure IV in the online-only Data Supplement). Because cytochalasin D treatment displaces cortactinactin, as well as caveolin-1, from the nonlipid raft regions ( Figure III in the online-only Data Supplement), caveolae formation in the lipid-rich domains may depend on AMPK/ SIRT1 regulation of the cortactin-F-actin complex. A possible mechanism is that AMPK phosphorylation followed by SIRT1 deacetylation enhances the interaction between the Lys-rich patch of cortactin with F-actin. Such an enhanced cortactin-F-actin interaction could lead to the translocation of the cortical-actin complex with caveolin-1 and eNOS in the lipid raft.
The AMPK/SIRT1-dependent regulation of caveolae via cortactin-F-actin is required for eNOS activation. The process can be activated mechanically or pharmacologically (ie, by PS or resveratrol), which suggests that cortactin-F-actin assembly is a common component for stimuli that increase eNOS-derived NO bioavailability. Much evidence demonstrates that eNOS trafficking from membrane caveolae to the cytoplasm is required for its activation, 25, 27, 38, 53 but our data reveal that this subcellular localization and translocation of eNOS depends on AMPK/SIRT1 coregulation of cortactin. The most likely explanation for this is that eNOS translocation requires cortactin-F-actin in an AMPK/ SIRT1-dependent manner. This postulation is supported by observations that cortactin T401D/9K/R (a gain-of-function mutant) is associated with higher levels of NO ( Figure 3F and 3G) and that F-actin disruption or caveolae diminishment impairs eNOS activity. 26, 27, 30 At the tissue level, metformin administration increased the eNOS translocation to the nonlipid raft in mouse ECs ( Figure VIIA en face confocal immunostaining ( Figure VIIB in the onlineonly Data Supplement). In relation to atherosclerosis, AMPK/ SIRT1 coregulation of cortactin-F-actin affects endothelial function preceding atherosclerosis, which would be, in part, because of impaired eNOS activity. The consistent increase in atherosclerosis in the thoracic aorta of ApoE -/-/cortactin +/- (Figure 6 ), ApoE -/-/AMPKα2 -/-, and ApoE -/-/EC-SIRT1 -/mice suggests that the flow-regulated cortactin-F-actin is associated with AMPK and SIRT1 activity. 5 Besides cortactin, cortical-actin complexes contain actin-related protein 2/3, neuronal WASP/WAVE, and dynamin-2. Whether these proteins affect ECs in the same manner as cortactin warrants further study. Although vascular smooth muscle cells (VSMCs) in the vasculature are not in direct contact with blood flow, the AMPK/SIRT1-cortactin signaling seems to be functional in VSMCs in 2 ways. First, AMPK/SIRT1-cortactin may positively regulate the redox state of VSMCs because AMPKα2 or cortactin knockdown results in an increased ROS level and NOX4 expression with concurrent decrease in SOD1 expression ( Figure VIII in the online-only Data Supplement). If so, the beneficial effect of AMPK and SIRT1 in VSMCs would be, in part, mediated through cortactin. 54, 55 Second, AMPK/ SIRT1-cortactin signaling in ECs seems to affect the homeostasis of VSMCs. Supporting this postulation, ECs treated with metformin or EC transfected with T401D are associated with an increased cGMP level in the conditioned media ( Figure IXB in the online-only Data Supplement), as well as a decreased ROS level in the cocultured VSMCs ( Figure IXC in the online-only Data Supplement).
What appears to argue against the above conclusions is that endothelial-specific overexpression of caveolin-1 with an attendant increase in caveolae is atherogenic, and caveolin-1 knockout in the ApoE-null background decreases atherosclerosis. [56] [57] [58] However, endothelium from caveolin -/mice have higher levels of NO, which is usually predictive of atheroprotection. 58, 59 Thus, caveolae abundance resulting from gene manipulations is not predictive of atherogenesis. Caveolae are signaling hubs harboring an array of both pro-and antiinflammatory molecules. The dynamic interactions of these caveolae-associated molecules with the cortical-actin complex that includes cortactin may be more important for modulation of the endothelial phenotype than level of caveolin-1. As discussed above, cortactin +/mice with decreased levels of caveolae ( Figure 5A ) exhibit a proinflammatory and dysfunctional endothelial phenotype. In contrast, eNOS activity is reduced and the flow-induced dilation is impaired in vessels from cortactin +/mice ( Figure 5C through 5E ). Furthermore, ApoE -/-/cortactin +/mice show increased atherosclerosis ( Figure 6C ). Because atheroprotective flow-activated AMPK and SIRT1 can directly modulate eNOS activity via posttranslational modifications, 4,5 our findings provide added complexity to AMPK/SIRT1 regulation of eNOS that involves cortactin-F-actin dynamics.
Previous studies demonstrate that the cortactin-dependent pathways are activated by sphingosine 1-phosphate and that sphingosine 1-phosphate is associated with highdensity lipoprotein. 48, [60] [61] [62] Related to these findings, it was indicated that synthetic sphingosine 1-phosphate analogs ameliorate atherosclerosis. 63, 64 The clinical implication of the current study, together with those previous, is that the atheroprotective effect exerted by AMPK/SIRT1 and sphingosine 1-phosphate signaling maybe mediated through cortactin.
Sources of Funding
This work was supported in part by National Institutes of Health research grants R01HL105318, R01HL106579, and R01HL108735 (J.Y.-J. Shyy), R01ES019873 (Y. Wang).
